Pasar al contenido principal

SINTESIS DE COMPUESTOS CON MECANISMOS INNOVADORES CONTRA ENFERMEDADES NEURODEGENERATIVAS Y DOLOR NEUROPATICO

PID2020-118127RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 38
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

  • Codony, Sandra|||0000-0003-0539-673X
  • Pont, Caterina|||0000-0001-9118-0892
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Di Pede-Mattatelli, Ania
  • Calvó-Tusell, Carla|||0000-0003-2681-8460
  • Feixas, Ferran|||0000-0001-5147-0000
  • Osuna, Sílvia|||0000-0003-3657-6469
  • Jarné-Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela|||0000-0002-2890-3856
  • Loza, María Isabel|||0000-0003-4730-0863
  • Brea, José|||0000-0002-5523-1979
  • Pérez, Belén|||0000-0001-5801-1704
  • Bartra, Clara
  • Sanfeliu i Pujol, Coral|||0000-0002-9004-1206
  • Juárez-Jiménez, Jordi|||0000-0003-1464-1397
  • Morisseau, Christophe
  • Hammock, Bruce D.|||0000-0003-1408-8317
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Vázquez, Santiago|||0000-0002-9296-6026
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)-TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy

  • Camarero-Hoyos, Claudia
  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen|||0000-0003-4074-5624
  • Fallica, Antonino Nicolò|||0000-0003-1899-8414
  • Román-Álamo, Lucía
  • Ramírez Moreno, Miriam|||0000-0002-9823-319X
  • Portabella, Emma
  • Cuspinera, Ona
  • Currea-Ayala, Daniela
  • Orozco-Quer, Marc
  • Ribera, Maria
  • Siden-Kiamos, Inga|||0000-0003-1572-5840
  • Spanos, Lefteris
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Crespo, Benigno
  • Viera, Sara|||0000-0002-2025-4804
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Zarzuela, Francesc
  • Urtasun, Nerea|||0000-0003-1093-2269
  • Pérez-Torras, Sandra|||0000-0002-2785-5602
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Arce, Elsa M.|||0000-0003-3757-5468
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
Background/Objectives : YAT2150 is a first-in-class antiplasmodial compound that has been recently proposed as a new interesting drug for malaria therapy. Methods/Results : The fluorescence of YAT2150 rapidly increases upon its entry into Plasmodium, a property that can be of use for the design of highly sensitive diagnostic approaches. YAT2150 blocks the in vitro development of the ookinete stage of Plasmodium and, when added to an infected blood meal, inhibits oocyst formation in the mosquito. Thus, the compound could possibly contribute to future transmission-blocking antimalarial strategies. Cell influx/efflux studies in Caco-2 cells suggest that YAT2150 is internalized by endocytosis and also through the OATP2B1 transporter, whereas its main export route would be via OSTα. YAT2150 has an overall favorable drug metabolism and pharmacokinetics profile, and its moderate cytotoxicity can be significantly reduced upon encapsulation in immunoliposomes, which leads to a dramatic increase in the drug selectivity index to values close to 1000. Although YAT2150 binds amyloid-forming peptides, its in vitro fluorescence emission is stronger upon association with peptides that form amorphous aggregates, suggesting that regions enriched in unstructured proteins are the preferential binding sites of the drug inside Plasmodium cells. The reduction of protein aggregation in the parasite after YAT2150 treatment, which has been suggested to be directly related to the drug's mode of action, is also observed following treatment with quinoline antimalarials like chloroquine and primaquine. Conclusions : Altogether, the data presented here indicate that YAT2150 can represent the spearhead of a new family of compounds for malaria diagnosis and therapy due to its presumed novel mode of action based on the interaction with functional protein aggregates in the pathogen.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

  • Pont, Caterina|||0000-0001-9118-0892
  • Sampietro, Anna|||0000-0002-1837-2051
  • Pérez-Areales, Francisco Javier|||0000-0001-9525-9346
  • Cristiano, Nunzia
  • Albalat, Agustí
  • Pérez, Belén|||0000-0001-5801-1704
  • Bartolini, Manuela|||0000-0002-2890-3856
  • De Simone, Angela|||0000-0003-1915-458X
  • Andrisano, Vincenza|||0000-0003-4396-1904
  • Barenys, Marta
  • Teixido, Elisabet|||0000-0002-0146-876X
  • Sabaté Lagunas, Raimon|||0000-0003-3894-2362
  • Loza García, María Isabel
  • Brea, José|||0000-0002-5523-1979
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
Multitarget compounds have emerged as promising drug candidates to cope with complex multifactorial diseases, like Alzheimer's disease (AD). Most multitarget compounds are designed by linking two pharmacophores through a tether chain (linked hybrids), which results in rather large molecules that are particularly useful to hit targets with large binding cavities, but at the expense of suffering from suboptimal physicochemical/pharmacokinetic properties. Molecular size reduction by removal of superfluous structural elements while retaining the key pharmacophoric motifs may represent a compromise solution to achieve both multitargeting and favorable physicochemical/PK properties. Here, we report the stepwise structural simplification of the dihydroxyanthraquinone moiety of a rhein-huprine hybrid lead by hydroxy group removal-ring contraction-ring opening-ring removal, which has led to new analogs that retain or surpass the potency of the lead on its multiple AD targets while exhibiting more favorable drug metabolism and pharmacokinetic (DMPK) properties and safety profile. In particular, the most simplified acetophenone analog displays dual nanomolar inhibition of human acetylcholinesterase and butyrylcholinesterase (IC = 6 nM and 13 nM, respectively), moderately potent inhibition of human BACE-1 (48% inhibition at 15 µM) and Aβ42 and tau aggregation (73% and 68% inhibition, respectively, at 10 µM), favorable in vitro brain permeation, higher aqueous solubility (18 µM) and plasma stability (100/96/86% remaining in human/mouse/rat plasma after 6 h incubation), and lower acute toxicity in a model organism (zebrafish embryos; LC » 100 µM) than the initial lead, thereby confirming the successful lead optimization by structural simplification.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen
  • Biosca, Arnau
  • Caño-Prades, Omar
  • Román-Álamo, Lucía
  • Valle, Javier
  • Andreu Martínez, David
  • Moita, Diana
  • Prudêncio, Miguel
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome's propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen's viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC50 of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC50, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite's viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability

  • Román-Álamo, Lucía
  • Avalos-Padilla, Yunuen
  • Bouzón-Arnáiz, Inés
  • Iglesias, Valentin
  • Fernández Lajo, Jorge
  • Monteiro, Juan M.
  • Rivas, Luis
  • Fisa, Roser
  • Riera, Cristina
  • Andreu Martínez, David
  • Pintado-Grima, Carlos
  • Ventura, Salvador
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
The problems associated with the drugs currently used to treat leishmaniasis, including resistance, toxicity, and the high cost of some formulations, call for the urgent identification of new therapeutic agents with novel modes of action. The aggregated protein dye YAT2150 has been found to be a potent antileishmanial compound, with a half-maximal inhibitory concentration (IC50) of approximately 0.5 µM against promastigote and amastigote stages of Leishmania infantum. The encapsulation in liposomes of YAT2150 significantly improved its in vitro IC50 to 0.37 and 0.19 µM in promastigotes and amastigotes, respectively, and increased the half-maximal cytotoxic concentration in human umbilical vein endothelial cells to >50 µM. YAT2150 became strongly fluorescent when binding intracellular protein deposits in Leishmania cells. This fluorescence pattern aligns with the proposed mode of action of this drug in the malaria parasite Plasmodium falciparum, the inhibition of protein aggregation. In Leishmania major, YAT2150 rapidly reduced ATP levels, suggesting an alternative antileishmanial mechanism. To the best of our knowledge, this first-in-class compound is the only one described so far having significant activity against both Plasmodium and Leishmania, thus being a potential drug for the treatment of co-infections of both parasites., This work was supported by grants (i) Fundació La Marató de TV3, Ref. 201811 (X.F.-B.); (ii) PID2021-128325OB-I00 (X.F.-B.) and PID2020-118127RB-I00 (D.M.-T.), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033), which included ERDF funds; (iii) II Premis Innovació Campus Clínic 2022, Hospital Clínic de Barcelona (X.F.-B.); and (iv) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2021-SGR-00635 (S.V.) and 2021-SGR-00357 (D.M.-T.). Work at Pompeu Fabra University was supported by “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409) and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. Work at the Centro de Investigaciones Biológicas was supported by grants from MCIN Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER RD16/0027/0010 and CSIC PIE 201620E038. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Discovery and in vivo proof of concept of a highly potent dual inhibitor of soluble Epoxide Hydrolase and Acetylcholinesterase for the treatment of Alzheimer’s disease

  • Codony, Sandra
  • Pont, Caterina
  • Griñán Ferré, Christian
  • Pede-Mattatelli, Ania di
  • Calvó Tusell, Carla
  • Feixas, Ferrán
  • Osuna, Sílvia
  • Jarné Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Pérez, Belén
  • Bartra, Clara
  • Sanfeliu, Coral
  • Juárez Jiménez, Jordi
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz Torrero, Diego
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer’s disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)–TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

2-(Piperidin-4-yl)acetamides as potent inhibitors of soluble epoxide hydrolase with anti-inflammatory activity

  • Martín López, Juan
  • Codony, Sandra
  • Bartra, Clara
  • Morisseau, Christophe
  • Loza García, María Isabel
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea Floriani, José Manuel
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

  • Pont, Caterina
  • Sampietro, Anna
  • Pérez-Areales, F. Javier
  • Cristiano, Nunzia
  • Albalat, Agustí
  • Pérez, Belén
  • Bartolini, Manuela
  • De Simone, Angela
  • Andrisano, Vincenza
  • Barenys, Marta
  • Teixidó, Elisabet
  • Sabaté, Raimon
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Muñoz-Torrero, Diego
Multitarget compounds have emerged as promising drug candidates to cope with complex multifactorial diseases, like Alzheimer's disease (AD). Most multitarget compounds are designed by linking two pharmacophores through a tether chain (linked hybrids), which results in rather large molecules that are particularly useful to hit targets with large binding cavities, but at the expense of suffering from suboptimal physicochemical/pharmacokinetic properties. Molecular size reduction by removal of superfluous structural elements while retaining the key pharmacophoric motifs may represent a compromise solution to achieve both multitargeting and favorable physicochemical/PK properties. Here, we report the stepwise structural simplification of the dihydroxyanthraquinone moiety of a rhein-huprine hybrid lead by hydroxy group removal-ring contraction-ring opening-ring removal, which has led to new analogs that retain or surpass the potency of the lead on its multiple AD targets while exhibiting more favorable drug metabolism and pharmacokinetic (DMPK) properties and safety profile. In particular, the most simplified acetophenone analog displays dual nanomolar inhibition of human acetylcholinesterase and butyrylcholinesterase (IC50 = 6 nM and 13 nM, respectively), moderately potent inhibition of human BACE-1 (48% inhibition at 15 µM) and Aβ42 and tau aggregation (73% and 68% inhibition, respectively, at 10 µM), favorable in vitro brain permeation, higher aqueous solubility (18 µM) and plasma stability (100/96/86% remaining in human/mouse/rat plasma after 6 h incubation), and lower acute toxicity in a model organism (zebrafish embryos; LC50 >> 100 µM) than the initial lead, thereby confirming the successful lead optimization by structural simplification.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity

  • Martín-López, Juan
  • Codony, Sandra
  • Bartra Cabré, Clara
  • Morisseau, Christophe
  • Loza, María Isabel
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU., This research was funded by the Spanish Ministerio de Economía, Industria y Competitividad (Grants SAF2017-82771-R to S.V., PID2019-106285RB-C22 to C.S.), Grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V., the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

A new family of subnanomolar inhibitors of soluble epoxide hydrolase

  • Escolano, Carmen
  • Bagán, Andrea
  • Turcu, Andreea L.
  • Morisseau, Christophe
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Vázquez, Santiago
Trabajo presentado en el ASPET Annual Meeting at Experimental Biology 2022, celebrado en Philadelphia, PA (Estados Unidos), del 2 al 5 de abril de 2022, Epoxyeicosatrienoic acids (EETs) are endogenous chemical mediators derived from arachidonic acid that show anti-inflammatory, antihypertensive, analgesic, angiogenic, and antiatherosclerotic effects. Soluble epoxide hydrolase (sEH) converts EETs to the corresponding dihydroxyeicosatrienoic acids (DHETs), whereby the biological effects of EETs are diminished, eliminated, or altered.1 Therefore, inhibition of sEH has been suggested as a novel pharmacological approach for the treatment of pain-related disorders and various inflammatory diseases, and a few sEH inhibitors (sEHI) have reached clinical trials, This research was funded by Grants PID2020-118127RB-I00 and PID2019-107991RB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” to S.V. and C.E. Financial support from Generalitat de Catalunya (2017 SGR106) and Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), to S.V., and from the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. are acknowledged. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01DK103616 to B.D.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, I.
  • Avalos-Padilla, Y.
  • Biosca, A.
  • Caño-Prades, O.
  • Román-Álamo, L.
  • Valle, Javier
  • Andreu, David
  • Moita, D.
  • Prudêncio, M.
  • Arce, E. M.
  • Muñoz-Torrero, Diego
  • Fernàndez-Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome’s propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen’s viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite’s viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia phenotypic changes induced by monomeric C-reactive protein: New perspectives against neuroinflammation in Alzheimer's disease

  • Yuan, Yi
  • Bartra Cabré, Clara
  • Valdes Quiroz, Haydée
  • Martín-López, Juan
  • Mullins, Joseph J.
  • Martínez, Noemí
  • Codony, Sandra
  • García-Lara, Elisa
  • Sawkulycz, Xenia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
  • Slevin, Mark
  • Sanfeliu, Coral
Resumen del trabajo presentado en el XII Simposi de Neurobiologia, Societat Catalana de Biologia, celebrado en Barcelona (España), los días 7 y 8 de junio de 2022, Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide. Neuroinflammation is a crucial neuropathological trait in AD, although the underlying mechanisms are not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of blood CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology in experimental models. Here we analysed the phenotypic changes induced by mCRP in microglia, the main effector cells of the inflammatory response. Then we tested the protective action of inhibiting the soluble epoxide hydrolase enzyme (sEH), a promising druggable target in AD. sEH inhibitors (sEHi) increase intracellular levels of anti-inflammatory epoxyeicosatrienoic acids (EETs). BV2 microglial cells were incubated with 50 or 100 µM mCRP for 24 h. Leading molecules of chemical families of newly synthesized sEHi (UB-JML-99 and UB-JM-39) were used for protective assays. mCRP activated the nitric oxide pathway as shown by increased release of nitric oxide and higher gene expression of iNOS, whereas sEHi agents blocked these effects. mCRP increased the release of TNF¿ into the media and the expression of pro-inflammatory cytokines and chemokines. Furthermore, mCRP modified the epigenetic microglial phenotype suggesting a dysregulated pattern. sEHi generally inhibited damaging effects of mCRP with a higher potency than the standard compound TPPU. Overall we demonstrated that mCRP directly activates microglia inflammatory pathways and may contribute to the triggering and progression of AD. Moreover, sEHi were confirmed as effective therapeutic molecules against neuroinflammation in an AD scenario., Agencia Estatal de Investigación (España); Ministerio de Ciencia, Innovación y Universidades (España); Generalitat de Catalunya
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble Epoxide Hydrolase Inhibitors: Design, Synthesis, in vitro Profiling and in vivo Evaluation in Murine Models of Pain

  • Vázquez, Santiago
  • Codony, Sandra
  • Entrena, José M.
  • Jora, Beatrice
  • González-Cano, Rafael
  • Loza, María Isabel
  • Brea, José Manuel
  • Morisseau, Christophe
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Cobos, Enrique J.
Epoxyeicosatrienoic acids (EETs) are endogenous chemical mediators that show anti-inflammatory, antihypertensive, and analgesic effects. Soluble epoxide hydrolase (sEH) converts EETs to their corresponding dihydroxyeicosatrienoic acids, whereby the biological effects of EETs are modified. Therefore, inhibition of sEH has been suggested as a novel pharmacological approach for the treatment of inflammatory and pain-related disorders.1 Recently, we have discovered a new family of sEH inhibitors (sEHI) featuring a unique benzohomoadamantane scaffold. In a murine model of cerulein-induced acute pancreatitis, the administration of a selected candidate significantly reduced pancreatic damage and improved the health status of the animals.2 Herein we report further structure-activity relationships within this series of benzohomoadamantane-derived sEHI. Most of the novel derivatives were endowed with low nanomolar or even subnanomolar IC50 values at the human, murine and rat sEH. Further in vitro profiling (solubility, cytotoxicity, metabolic stability, selectivity, permeability, etc.) and pharmacokinetic studies permitted us to select a candidate for in vivo efficacy studies. This candidate reduced pain in the capsaicin-induced model of allodynia in a dose-dependent manner and outperformed other sEHI tested. In summary, these novel results and the previously reported studies using other families of sEHI, strongly suggest that sEH may be a target of clinical interest for managing pain.3 References: 1-Sun, C.-P.; Zhang, X.-Y.; Morisseau, C.; Hwang, S. H.; Zhang, Z.-J.; Hammock, B. D.; Ma, X.-C. J. Med. Chem. 2021, 64, 184-215. 2-Codony, S.; Calvó-Tusell, C.; Valverde, E.; Osuna, S.; Morisseau, C.; Loza, M.I.; Brea, J.; Pérez, C.; Rodríguez-Franco, M.I.; Pizarro-Delgado, J.; Corpas, R.; Griñán-Ferré, C.; Pallàs, M.; Sanfeliu, C.; Vázquez-Carrera, M.; Hammock, B. D.; Feixas, F.; Vázquez, S. J. Med. Chem., 2021, 64, 5429-5446. 3-McReynolds, C.; Morisseau, C.; Wagner, K.; Hammock, B. D. Adv. Exp. Med. Biol. 2020, 1274, 71-99., This research was funded by Grant PID2020-118127RB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” to S.V. Financial support from Fundació Bosch i Gimpera (F2I grant), to S.V., and from the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. are acknowledged. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis

  • Pérez-Areales, F. Javier
  • Sampietro, A.
  • Martínez, P.
  • Arce, E. M.
  • Galdeano, Carles
  • Muñoz-Torrero, Diego
Multitarget anti-Alzheimer agents are the focus of very intensive research. Through a comprehensive bibliometric analysis of the publications in the period 1990–2020, we have identified trends and potential gaps that might guide future directions. We found that: (i) the number of publications boomed by 2011 and continued ascending in 2020; (ii) the linked-pharmacophore strategy was preferred over design approaches based on fusing or merging pharmacophores or privileged structures; (iii) a significant number of in vivo studies, mainly using the scopolamine-induced amnesia mouse model, have been performed, especially since 2017; (iv) China, Italy and Spain are the countries with the largest total number of publications on this topic, whereas Portugal, Spain and Italy are the countries in whose scientific communities this topic has generated greatest interest; (v) acetylcholinesterase, β-amyloid aggregation, oxidative stress, butyrylcholinesterase, and biometal chelation and the binary combinations thereof have been the most commonly pursued, while combinations based on other key targets, such as tau aggregation, glycogen synthase kinase-3β, NMDA receptors, and more than 70 other targets have been only marginally considered. These results might allow us to spot new design opportunities based on innovative target combinations to expand and diversify the repertoire of multitarget drug candidates and increase the likelihood of finding effective therapies for this devastating disease., This research was funded by the grants PID2020-118127RB-I00 and RTI2018-096429-B-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, and 2017SGR106 and 2019LLAV00017 from AGAUR
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors: design, synthesis, in vitro profiling and in vivo evaluation in murine models of pain

  • Vázquez, Santiago
  • Codony, Sandra
  • Entrena, José M.
  • Jora, Beatrice
  • González-Cano, Rafael
  • Loza, María Isabel
  • Brea, José Manuel
  • Morisseau, Christophe
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Cobos, Enrique J.
Trabajo presentado en el ASPET Annual Meeting at Experimental Biology 2022, celebrado en Philadelphia, PA (Estados Unidos), del 2 al 5 de abril de 2022, This research by the Grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V. Financial support from Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), to S.V., and from the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. are acknowledged. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of Dual Aβ/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer's Disease

  • Gandini, Annachiara
  • Gonçalves, Ana Elisa
  • Strocchi, Silvia
  • Albertini, Claudia
  • Janockova, Jana
  • Tramarin, Anna
  • Grifoni, Daniela
  • Poeta, Eleonora
  • Soukup, Ondrej
  • Muñoz-Torrero, Diego
  • Monti, Barbara
  • Sabate, Raimon
  • Bartolini, Manuela
  • Legname, Giuseppe
  • Bolognesi, Maria Laura
Alzheimer's disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid-β (Aβ) and Tau proteins are prototypical AD hallmarks, as well as validated drug targets. Accumulating evidence now suggests that they synergistically contribute to disease pathogenesis. This could not only help explain negative results from anti-Aβ clinical trials but also indicate that therapies solely directed at one of them may have to be reconsidered. Based on this, herein, we describe the development of a focused library of 2,4-thiazolidinedione (TZD)-based bivalent derivatives as dual Aβ and Tau aggregation inhibitors. The aggregating activity of the 24 synthesized derivatives was tested in intact Escherichia coli cells overexpressing Aβ42 and Tau proteins. We then evaluated their neuronal toxicity and ability to cross the blood-brain barrier (BBB), together with the in vitro interaction with the two isolated proteins. Finally, the most promising (most active, nontoxic, and BBB-permeable) compounds 22 and 23 were tested in vivo, in a Drosophila melanogaster model of AD. The carbazole derivative 22 (20 μM) showed extremely encouraging results, being able to improve both the lifespan and the climbing abilities of Aβ42 expressing flies and generating a better outcome than doxycycline (50 μM). Moreover, 22 proved to be able to decrease Aβ42 aggregates in the brains of the flies. We conclude that bivalent small molecules based on 22 deserve further attention as hits for dual Aβ/Tau aggregation inhibition in AD., This work was conducted by A.E.G during a scholarship at the University of Bologna, Italy, supported by the International Cooperation Program CAPES/ PDSE Process #88881.187586/ 2018-01. O.S. acknowledges the Ministry of Education, Youth and Sports of the Czech Republic (project ERDF no. CZ.02.1.01/0.0/0.0/18_069/0010054). DMT: grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033. M.L.B. and M.B. would also like to acknowledge the University of Bologna (RFO 2019) and the Italian Ministry of Education, Universities and Research (MIUR), for financial support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, in vitro profiling and in vivo evaluation of benzohomoadamantane-based ureas for visceral pain: a new indication for soluble epoxide hydrolase inhibitors

  • Codony, Sandra
  • Entrena, José M.
  • Calvó-Tusell, Carla
  • Osuna, Sílvia
  • Jora, Beatrice
  • González-Cano, Rafael
  • Corpas, Rubén
  • Morisseau, Christophe
  • Pérez, Belén
  • Barniol-Xicota, Marta
  • Griñán-Ferré, Christian
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Martínez, Antón L.
  • Loza, María Isabel
  • Pallàs, Mercè
  • Verhelst, Steven H. L.
  • Sanfeliu, Coral
  • Feixas, Ferran
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spanish MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (Grant PID2020-118127RB-I00 to S.V. and Grant PID2019-106285RB to M.P. and C.S.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF661160-MetAccembly to F.F.). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant) and the Spanish Society of Medicinal Chemistry (SEQT) and Lilly for an “Award for Novel Researchers in the Discovery and Development of New Drugs”. M.B.X. acknowledges FWO for a post-doctoral fellowship (no. 12Y0720N). S.H.L.V. acknowledges the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin, and the Bundesministerium für Bildung und Forschung. F.F. acknowledges Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cognitive Decline and BPSD Are Concomitant with Autophagic and Synaptic Deficits Associated with G9a Alterations in Aged SAMP8 Mice

  • Vasilopoulou, Foteini
  • Bellver-Sanchis, Aina
  • Companys-Alemany, Júlia
  • Jarne-Ferrer, Júlia
  • Irisarri, Alba
  • Palomera-Ávalos, Verónica
  • Gonzáez-Castillo, Celia
  • Ortuño-Sahagún, Daniel
  • Sanfeliu, Coral
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
Behavioural and psychological symptoms of dementia (BPSD) are presented in 95% of Alzheimer’s Disease (AD) patients and are also associated with neurotrophin deficits. The molecular mechanisms leading to age-related diseases are still unclear; however, emerging evidence has suggested that epigenetic modulation is a key pathophysiological basis of ageing and neurodegeneration. In particular, it has been suggested that G9a methyltransferase and its repressive histone mark (H3K9me2) are important in shaping learning and memory by modulating autophagic activity and synaptic plasticity. This work deepens our understanding of the epigenetic mechanisms underlying the loss of cognitive function and BPSD in AD. For this purpose, several tasks were performed to evaluate the parameters of sociability (three-chamber test), aggressiveness (resident intruder), anxiety (elevated plus maze and open field) and memory (novel object recognition test) in mice, followed by the evaluation of epigenetic, autophagy and synaptic plasticity markers at the molecular level. The behavioural alterations presented by senescence-accelerated mice prone 8 (SAMP8) of 12 months of age compared with their senescence-accelerated mouse resistant mice (SAMR1), the healthy control strain was accompanied by age-related cognitive deficits and alterations in epigenetic markers. Increased levels of G9a are concomitant to the dysregulation of the JNK pathway in aged SAMP8, driving a failure in autophagosome formation. Furthermore, lower expression of the genes involved in the memory-consolidation process modulated by ERK was observed in the aged male SAMP8 model, suggesting the implication of G9a. In any case, two of the most important neurotrophins, namely brain-derived neurotrophic factor (Bdnf) and neurotrophin-3 (NT3), were found to be reduced, along with a decrease in the levels of dendritic branching and spine density presented by SAMP8 mice. Thus, the present study characterizes and provides information regarding the non-cognitive and cognitive states, as well as molecular alterations, in aged SAMP8, demonstrating the AD-like symptoms presented by this model. In any case, our results indicate that higher levels of G9a are associated with autophagic deficits and alterations in synaptic plasticity, which could further explain the BPSD and cognitive decline exhibited by the model., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) by the grants PDC2021-121096/AEI/10.13039/501100011033 and PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033, and 2017SGR106 and 2019LLAV00017 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chlorpyrifos Oxon Activates Glutamate and Lysine for Protein Cross-linking

  • Muñoz-Torrero, Diego
  • Schopfer, Lawrence M.
  • Lockridge, Oksana
Chronic low-dose exposure to organophosphorus (OP) toxicants is correlated with an increase in the risk of impaired cognition and neurodegenerative diseases. A mechanism to explain this relationship is needed. We suggest that the formation of organophosphate-induced high-molecular-weight protein aggregates that disrupt cell function may be the missing link. It has been demonstrated that such aggregation can be promoted by OP-labeled lysine. Alternatively, OP-labeled glutamate may be the initiator. To test this hypothesis, we treated MAP-rich tubulin Sus scrofa and human transglutaminase with chlorpyrifos oxon. Trypsin-digested proteins were subjected to liquid chromatography-tandem mass spectrometry followed by Protein Prospector searches to identify diethyl phosphate adducts and cross-linked peptides. We report the presence of diethyl phosphate adducts on the side chains of glutamate, lysine, and tyrosine, as well as cross-links between glutamate and lysine. Glutamate-lysine cross-linking could be initiated either by diethyl phosphate-activated glutamate or by diethyl phosphate-activated lysine to form stable isopeptide bonds between and within proteins. It was concluded that organophosphate-induced high-molecular-weight protein aggregates could promote brain dysfunction., This work was supported in part by the Fred & Pamela Buffet Cancer Center Support Grant [grant number P30CA036727] from the National Institutes of Health and by Ministerio de Ciencia e Innovacioń and Agencia Estatal de Investigacioń MCIN/AEI/10.13039/501100011033 [grant number PID2020-118127RB-I00].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

  • Codony, Sandra
  • Pont, Caterina
  • Griñán-Ferré, Christian
  • Di Pede-Mattatelli, Ania
  • Calvó-Tusell, Carla
  • Feixas, Ferran
  • Osuna, Sílvia
  • Jarné-Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Juárez-Jiménez, Jordi
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)-TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration., This work was supported by grants PID2020-118127RB-I00, SAF2017-82771-R, PID2020-115683GA-I00, PGC2018- 102192-B-I00, PID2019-106285RB, and RTI2018-101032-JI00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, ED431C 2018/21 and ED431G 2019/02 from Xunta de Galicia, and 2017SGR106, 2017SGR1707, and 2019LLAV00017 from AGAUR. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Fellowships from Ministerio de Educación, Cultura y Deporte to C.P. (FPU15/01131), from the University of Barcelona to S.C., and a starting grant from the European Research Council (ERC-2015-StG-679001- NetMoDEzyme) to S.O. are gratefully acknowledged. We thank Ms. Cecilia Mariani for technical assistance in the assays with mAChE., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

A new family of soluble epoxide hydrolase inhibitors: in vivo evaluation in a murine model of chemotherapy-induced neuropathic pain

  • Vázquez, Santiago
  • Codony, Sandra
  • Jora, Beatrice
  • Turcu, Andreea L.
  • Calvó-Tusell, Carla
  • Morisseau, Christophe
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Pérez, Belén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Hammock, Bruce D.
  • Osuna, Sílvia
  • Feixas, Ferran
  • Cobos, Enrique J.
Trabajo presentado en el 22nd European Symposium on Organic Chemistry, celebrado en Ghent (Bélgica), del 9 al 13 de julio de 2023, Thisworkwasfundedbythethe Grant PID2020-118127RB-I00 fundedbyMCIN/AEI/10.13039/501100011033andby“ERDFAwayofmakingEurope”toS.V.,andthe Xunta de Galicia (ED431G2019/02andED431C2018/21).PartialsupportwasprovidedbyNIH-NIEHSRiverAwardR35ES03443,NIH-NIEHSSuperfundProgramP42ES004699,NINDSR01DK107767,andNIDDKR01DK103616toB.D.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

High levels of anti-inflammatory epoxyeicosatrienoic acids may improve neurodevelopment in children prenatally exposed to mercury

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferrán
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
Trabajo presentado en Neuroscience 2023, celebrado en Washington D. C. (Estados Unidos), del 11 al 15 de noviembre de 2023, A balanced concentration of polyunsaturated fatty acids (PUFA) in the prenatal stage is essential for children¿s neurodevelopment. Also, animal studies showed that high levels of anti-inflammatory PUFA metabolites in the embryonic brain protect against genetic or environmental insults that would otherwise cause cognitive impairment. Here we used liquid chromatography - mass spectrometry to analyze oxylipins, the oxygenated metabolites of PUFA, in the placenta tissue (N=12) and cord blood plasma (N=39) of children from the INMA cohort (Valencia, Spain). Both tissues were characterized for total Hg levels as a reference for developmental neurotoxic MeHg exposure during pregnancy and distributed in low and high Hg groups. Deleterious effects of high Hg were confirmed in the placenta as decreased proteasome activity and inhibitory epigenetic changes. Children¿s neurodevelopment was assessed using the Bayley (14 months) and McCarthy (5 years) scales. Spearman correlation coefficients were calculated between scores and oxylipin levels. We also analyzed cortical brain tissue from wild type and transgenic Alzheimer's disease (5XFAD) mice dosed for 2 months with vehicle or a soluble epoxide hydrolase enzyme (sEH) inhibitor, UB-BJ-02 (5 mg/Kg, N=5/group). Inhibition of sEH increases levels of the potent anti-inflammatory epoxyeicosatrienoic acids (EETs) by inhibiting their hydrolysis to dihydro-EETs (DiHETs). We found that DiHETs were increased in the placenta of high Hg group. Furthermore, the mental and psychomotor development of 14-month-old children correlates positively with DiHETs levels in both placenta and cord blood tissues. Interestingly, cord blood DiEHTs positively correlate with working memory at 5 years. Thus we suggest that higher levels of DiHETs indicate higher synthesis of their anti-inflammatory EETs precursors. Accordingly, placenta levels of EETs correlate with mental development at 14 months of age. Other oxylipin changes also suggested an involvement of inflammatory mechanisms in the neurodevelopment of children exposed to MeHg. In general, higher levels of markers of resolved inflammation or final stable metabolites in the placenta and cord blood tissues correlate with better neuropsychological development in children exposed to environmental MeHg. Finally, mouse treatment with the drug UB-BJ-02 showed increased EETs and decreased pro-inflammatory markers in brain tissue. Both human and experimental results showed that EETs are prominent anti-inflammatory metabolites and support sEH inhibition as an anti-inflammatory treatment to increase brain resilience to environmental risk of neurodevelopmental damage., Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB and PDC2021-121096); European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; 2021-SGR-357 from AGAUR; H2020 874583; FIS/FEDER 19/1338; 16/1288; AICO/2020/285; CIAICO/2021/132; MS20/0006; MS21/0133
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Trabajo presentado en el 36th ECNP Congress, celebrado en Barcelona (España), del 7 al 10 de octubre de 2023, Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Funding: Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress

  • Peyman, Mona
  • Barroso, Emma
  • Turcu, Andreea L.
  • Estrany Jr., Francesc
  • Smith, Dáire
  • Jurado-Aguilar, Javier
  • Rada, Patricia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Valverde, Ángela M.
  • Palomer, Xavier
  • Galdeano, Carles
  • Vázquez, Santiago
  • Vázquez-Carrera, Manuel
Soluble epoxide hydrolase (sEH) is a drug target with the potential for therapeutic utility in the areas of inflammation, neurodegenerative disease, chronic pain, and diabetes, among others. Proteolysis-targeting chimeras (PROTACs) molecules offer new opportunities for targeting sEH, due to its capacity to induce its degradation. Here, we describe that the new ALT-PG2, a PROTAC that degrades sEH protein in the human hepatic Huh-7 cell line, in isolated mouse primary hepatocytes, and in the liver of mice. Remarkably, sEH degradation caused by ALT-PG2 was accompanied by an increase in the phosphorylated levels of AMP-activated protein kinase (AMPK), while phosphorylated extracellular-signal-regulated kinase 1/2 (ERK1/2) was reduced. Consistent with the key role of these kinases on endoplasmic reticulum (ER) stress, ALT-PG2 attenuated the levels of ER stress and inflammatory markers. Overall, the findings of this study indicate that targeting sEH with degraders is a promising pharmacological strategy to promote AMPK activation and to reduce ER stress and inflammation., This study was partly supported by grants RTI2018-093999-B-100 and PID2021-122116OB-I00 (M.V-C.), PID2020-118127RB-I00 (S.V.), PID2021-127693OB-I00 (C.G.) and PID2021-122766OB-I00 (A.M.V.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. CERCA Programme/Generalitat de Catalunya. Partial support was provided by NIH – NIEHS (RIVER Award) R35 ES030443-01, NIH – NIEHS (Superfund Award) P42 ES004699 and NIH Counter Act Award U54 NS127758 (B.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability

  • Román-Álamo, Lucía
  • Ávalos-Padilla, Yunuen
  • Bouzón-Arnáiz, Inés
  • Iglesias, Valentín
  • Fernández-Lajo, Jorge
  • Monteiro, Juan M.
  • Rivas, Luis
  • Fisa, Roser
  • Riera, Cristina
  • Andreu, David
  • Pintado-Grima, Carlos
  • Ventura, Salvador
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez-Busquets, Xavier
27 p.-9 fig.-3 tab., The problems associated with the drugs currently used to treat leishmaniasis, including resistance, toxicity, and the high cost of some formulations, call for the urgent identification of new therapeutic agents with novel modes of action. The aggregated protein dye YAT2150 has been found to be a potent antileishmanial compound, with a half-maximal inhibitory concentration (IC50) of approximately 0.5 µM against promastigote and amastigote stages of Leishmania infantum. The encapsulation in liposomes of YAT2150 significantly improved its in vitro IC50 to 0.37 and 0.19 µM in promastigotes and amastigotes, respectively, and increased the half-maximal cytotoxic concentration in human umbilical vein endothelial cells to >50 µM. YAT2150 became strongly fluorescent when binding intracellular protein deposits in Leishmania cells. This fluorescence pattern aligns with the proposed mode of action of this drug in the malaria parasite Plasmodium falciparum, the inhibition of protein aggregation. In Leishmania major, YAT2150 rapidly reduced ATP levels, suggesting an alternative antileishmanial mechanism. To the best of our knowledge, this first-in-class compound is the only one described so far having significant activity against both Plasmodium and Leishmania, thus being a potential drug for the treatment of co-infections of both parasites., Ref. 201811/Fundació la Marató de TV3 (Fundació la Marató) PID2021-128325OB-I00/Ministerio de Ciencia e Innovación (MCIN) PID2020-118127RB-I00/Ministerio de Ciencia e Innovación (MCIN) 2021-SGR-00635/Generalitat de Catalunya (Government of Catalonia) 2021-SGR-00357/Generalitat de Catalunya (Government of Catalonia), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

New dual sEH-AChE inhibitors with amyloid antiaggreganting actiivy fo the treatment of Alzheimer's disease

  • Sampietro, Anna
  • Haberek, Wawrzyniec
  • Bellver, Aina
  • Griñán-Ferré, Christian
  • Pérez, Belén
  • Pérez de la Lastra Aranda, Carmen
  • Palomo, Valle
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Morisseau, Christophe
  • Sabaté, Raimon
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
Resumen del trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium, celebrado en Barcelona del 24 al 26 de abril de 2024
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Overcoming Pain Management: Unlocking the Power of Dual-Mechanism Compounds

  • Escriche, Celia
  • Sánchez, Javier
  • Pujol, Eugènia
  • Martínez-López, juan
  • Brea, José Manuel
  • Morisseau, Christophe
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Loza, María Isabel
  • Vázquez, Santiago
Trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium: Harnessing the Power of New Drug Modalities, celebrado en Barcelona del 24 al 26 de abril de 2024, This work was funded by the Grants PID2020-118127RB-I00, to S.V., and PID2021-121096-C22, to C.S., funded by MICIU/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”, and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. C.E.M. and J.S. thank the Spanish MICIU for PhD Grants (FPI program). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

N-substituted piperidines in benzohomoadamantane-based ureas: potent inhibitors of soluble epoxide hydrolase with anti-inflammatory activity

  • López-Ruiz, Alba
  • Codony, Sandra
  • Jora, Beatrice
  • Turcu, Andreea L.
  • Morisseau, Christophe
  • Loza, María Isabel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Vázquez, Santiago
Trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium: Harnessing the Power of New Drug Modalities, celebrado en Barcelona del 24 al 26 de abril de 2024, This work was funded by the Grant PID2020-118127RB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V., and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. A.L.R. thanks the Spanish MICIU for a PhD Grant (FPI program). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Uncovering the amyloid anti-aggregation potential of novel dual sEH-AChE inhibitors for Alzheimer's disease treatment

  • Sampietro, Anna
  • Haberek, Wawrzyniec
  • Bellver, Aina
  • Griñán-Ferré, Christian
  • Pérez, Belén
  • Pérez de la Lastra Aranda, Carmen
  • Palomo, Valle
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Morisseau, Christophe
  • Sabaté, Raimon
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
Resumen del trabajo presentado en el 14th Summer School on Medicines, celebrado en Ribeirão Preto, SP (Brasil), del 29 de junio al 5 de julio de 2024, Alzheimer's disease (AD) stands as the predominant cause of dementia globally, exhibiting a complex nature influenced by various underlying mechanisms that contribute to its onset and progression. In response to this complexity, there's a growing interest in multitarget drug design, aimed at addressing multiple disease mechanisms with a single compound. Among the myriad of implicated factors, three key players emerge: neuroinflammation, cholinergic deficit, and protein aggregation. To tackle these interconnected aspects, our approach involves: 1) combating neuroinflammation by inhibiting soluble epoxide hydrolase (sEH), thereby elevating the levels of its substrate, the anti-inflammatory epoxyeicosatrienoic acids (EETs); 2) elevating acetylcholine levels through acetylcholinesterase (AChE) inhibition to compensate the cholinergic deficit; and 3) interfering the spontaneous aggregation of amyloidogenic proteins, thereby pursuing a so far unexplored target combination profile. In our research, we present a novel class of inhibitors targeting both sEH and AChE that additionally possess amyloid anti-aggregating properties. These inhibitors were developed by linking sEH and AChE inhibitor pharmacophores through a suitable linker. The resulting hybrid compounds exhibit enhanced potency against sEH and AChE compared to standard inhibitors, having subnanomolar or single-digit nanomolar IC50 values. Moreover, they demonstrate significant inhibitory activity against beta-amyloid and tau aggregation, with inhibition rates surpassing 50% at a concentration of 10 M. Notably, some compounds do also inhibit the aggregation of TDP-43, a protein involved in various neurodegenerative disorders, including AD and amyotrophic lateral sclerosis (ALS). Furthermore, the majority of these compounds are nonneurotoxic in SH-SY5Y cells at concentrations up to 100 M, possess the ability to cross the bloodbrain barrier according to the PAMPA-BBB assay, and display moderate aqueous solubility and microsomal stability. Ongoing studies include pharmacokinetic evaluations and efficacy assessments in an AD mouse model using a lead compound, aiming to further elucidate its potential as a disease-modifying anti-AD drug candidate., This work was supported by grant PID2020-118127RB-I00 funded by MICIN/AEI/10.13039/501100011033 and 2021SGR00357 from AGAUR
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies

  • Jarne-Ferrer, Júlia
  • Sánchez, Javier
  • Codony, Sandra
  • Schneider, Marion
  • Müller, Christa E.
  • Sanfeliu, Coral
  • Franco, Rafael
  • Vazquez, Santiago
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer's disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays a pivotal role in neuroinflammation by hydrolyzing epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and neuroprotective properties, into pro-inflammatory dihydroepoxyeicosatrienoic acids (DHETs). Furthermore, the overexpression of the enzyme in the brains of AD patients and animal models of the disease highlights its relevance as a therapeutic target. Our previous studies, using the inhibitor UB-SCG-51 demonstrated that sEH inhibition regulates neuroinflammation and other mechanisms, such as the unfolded protein response pathway, while reducing autophagy, apoptosis, and neuronal death, thereby promoting neuroprotection. Building on these findings, we evaluated the arginine salt of the compound, designated UB-SCG-74, which offers improved oral absorption compared to that of UB-SCG-51 while retaining high permeability, potency, and selectivity. In experiments using 5XFAD mice, UB-SCG-74 treatment significantly improved cognition and synaptic plasticity, outperforming donepezil, a standard AD drug, and ibuprofen, an anti-inflammatory drug. Remarkably, these benefits persisted for 4 weeks after administration cessation, suggesting lasting therapeutic effects. Safety pharmacology studies showed no toxicity, supporting the advancement of UB-SCG-74 into preclinical regulatory evaluation. Our findings further indicate that sEH inhibition engages multiple neuroprotective pathways, potentially modifying both AD symptoms and disease progression, thus reinforcing its therapeutic potential., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and European Union NextGenerationEU/PRTR (PID2020-118127RB-I00/AEI/10.13039/501100011033 to S.V.; PDC2021-121096/AEI/10. 13039/501100011033 to M.P./C.S. PID2021-127693OB-I00 AEI/10.13039/501100011033 to C.G., PID2021-138079OB-I00 AEI/10.13039/501100011033 to M.P.), and Generalitat de Catalunya (2021 SGR 00357). J.S. was supported by the Research Personnel Training Program (FPI grant PRE2021-099446) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU), and Agencia Estatal de Investigación (AEI). C.G.F. and M.P. belong to María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona, CEX2021-001159-M, Ministry of Science and Innovation). C.E.M. is grateful for support by the Deutsche Forschungsgemeinschaft (DFG) within the Major Research Instrumentation scheme for a highly sensitive HPLC-MS instrument (QTRAP). The paid version of Biorender.com was utilized to prepare the illustrations, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial pro-inflammatory mechanisms induced by monomeric C-reactive protein are counteracted by soluble epoxide hydrolase inhibitors

  • Bartra, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Codony, Sandra
  • Valdés-Quiroz, Haydeé
  • Casal, Carme
  • Slevin, Mark
  • Máquez-Kisinousky, Leonardo
  • Planas, Anna M.
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Monomeric C-reactive protein (mCRP) is a pro-inflammatory molecule generated by the dissociation of native CRP. Clinical and experimental studies suggest that mCRP deposition in the brain induces Alzheimer's disease (AD) pathology and cognitive loss. Pathological neuroinflammation is increasingly suggested as relevant in AD. Innovative therapies against neuroinflammation are desperately needed, and inhibitors of the enzyme soluble epoxide hydrolase (sEH) are a promising new generation of anti-inflammatory drugs. Mouse primary microglia and BV2 cell line cultures were exposed to mCRP to analyze its pro-inflammatory mechanisms. sEH inhibitors, both newly synthesized UB-SCG-55 and UB-SCG-65, and the reference agent TPPU, were tested for their anti-inflammatory action against mCRP. Phenotypic changes were analyzed through cell imaging techniques, as well as molecular analysis of inflammatory mediators and gene activation pathways. Results show that mCRP triggers a pro-inflammatory response through three main inflammatory pathways: iNOS, NLRP3, and COX-2, followed by increased cytokine generation. Polarization of microglia toward a M1-like phenotype was confirmed by morphological analysis. Also, mCRP can bind to and cross the cell membrane, providing further insight into its mechanisms of action. sEH inhibitors were effective against mCRP induction of a reactive microglial phenotype. The first-line compound UB-SCG-55 emerged as the most potent anti-inflammatory against mCRP injury. Therefore, the direct activation of microglia by mCRP provides evidence of its role in triggering and exacerbating neurodegenerative diseases with a neuroinflammatory component, such as AD. Furthermore, the protection given by inhibitors of sEH confirms its potential as innovative drugs against deleterious effects of neuroinflammation., This research was funded by Spanish MICIU/AEI/10.13039/501100011033 [grants PID2019-106285 and PID2020-118127RB-I00]; MICIU/AEI/10.13039/501100011033 and EU Next Generation Funds/RTRP [grant PDC2021-121096]; and AGAUR, Catalonia [grant 2021SGR357]. Partial support was provided by NIH-NIEHS River Award R35 ES030443, NIH-NINDS U54 NS127758 (Counter Act Program), and NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health). We thank Xenia Sawkulycz (Manchester Metropolitan University, U.K.) for her contribution with the preparation of mCRP., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M. Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., this work was funded by the spanish Ministerio de ciencia, innovación y universidades, Miciu/aei/10.13039/501100011033: Grants PiD2020-118127RB-i00 and PiD2023-147004OB-i00 (to s.V.), PiD2019-108691RB-i00 (to e.J.c.),PDc2021-121096 (to M.P. and c.s.), PiD2021-127693OB-i00 (to c.G.), PiD2022-141676NB-i00 (to F.F.);PiD2021-129034NB-i00 and PDc2022-133950-i00 (to s.O.); the Generalitat de catalunya (2021 sGR 00357 and 2021sGR 00487); the european Research council (eRc-2015-stG-679001-NetMoDezyme and eRc-2022-coG-101088032 tos.O.); the Xunta de Galicia (eD431c 2022/20); and the european Regional Development Fund (eRDF); Ministry ofscience and innovation, spain, with funds from the european union NextGenerationeu (PRtRc17.i1) and theautonomous community of Galicia within the framework of the 2023 Biotechnology Plan applied to health (to M.i.l.and J.B.). Partial support was provided by Nih-Niehs River award R35 es030443 and, Nih-Niehs superfund ProgramP42 es004699 to B.D.h. the content is solely the responsibility of the authors and does not necessarily represent theofficial views of the National institutes of health. M.R.c. was granted access to i24 beamline by the Diamond lightsource for (proposal number: MX32787). s.c. and a.l.t. received PhD fellowships from the universitat de Barcelona(aPiF grant) and the spanish Ministerio de educación, cultura y Deporte (FPu15/00889 grant), respectively. a.B.-M.,c.e., and M.s.-c. were supported by the Research Personnel training Program (FPi grants PRe2019-087468,PRe2022-104952, and PRe2020-096203, respectively) of the spanish Ministerio de ciencia, innovación y universidades(Miciu) and agencia estatal de investigación (aei). Q.Q. is funded by the King’s-china scholarship council PhDscholarship programme. F.F. received spanish MiciNN for a Ramón y cajal fellowship (RYc2020-029552-i). c.c.-t.received science Postdoctoral Fellowship from a schmidt Futures program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain [Dataset]

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033: Grants PID2020-118127RB-I00 and PID2023-147004OB-I00 (to S.V.), PID2019-108691RB-I00 (to E.J.C.), PDC2021-121096 (to M.P. and C.S.), PID2021-127693OB-I00 (to C.G.), PID2022-141676NB-I00 (to F.F.); PID2021-129034NB-I00 and PDC2022-133950-I00 (to S.O.); the Generalitat de Catalunya (2021 SGR 00357 and 2021 SGR 00487); the European Research Council (ERC-2015-StG-679001-NetMoDEzyme and ERC-2022-CoG-101088032 to S.O.); the Xunta de Galicia (ED431C 2022/20); and the European Regional Development Fund (ERDF); Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health (to M.I.L. and J.B.). Partial support was provided by NIH-NIEHS River Award R35 ES030443 and, NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.R.C. was granted access to I24 beamline by the Diamond Light Source for (proposal number: MX32787). S.C. and A.L.T. received PhD fellowships from the Universitat de Barcelona (APIF grant) and the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/00889 grant), respectively. A.B.-M., C.E., and M.S.-C. were supported by the Research Personnel Training Program (FPI grants PRE2019-087468, PRE2022-104952, and PRE2020-096203, respectively) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI). Q.Q. is funded by the King’s-China Scholarship Council PhD Scholarship programme. F.F. received Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). C.C.-T. received Science Postdoctoral Fellowship from a Schmidt Futures program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of anti-inflammatory pathways by polyunsaturated fatty acid signaling may protect neurodevelopment in children prenatally exposed to methylmercury

  • Bartra, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferran
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Sanfeliu, Coral
Mercury is ubiquitous in the environment. Substantial levels of its organic form, methylmercury, pose a risk to fetal neurodevelopment through the maternal diet. Conversely, nutrients such as the polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (AA) promote neurodevelopment. We aimed to elucidate the neuroprotective role of PUFA signaling against prenatal methylmercury exposure in a Mediterranean fish-consuming area, addressing a critical gap in understanding nutritional modulation of neurotoxicity., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministerio de Ciencia: Innovación y Universidades and the Agencia Estatal de Investigación, MICIU/AEI/10.13039/501100011033 grants PID2019-106285RB, PID2020-118127RB and PID2022-139016OA-100, and grant PDC2021-121096 co-funded by the European Union - Next Generation EU/PRTR; the Spanish Instituto de Salud Carlos III (ISCIII) and co-funded by the Europen Union, grants FI21/00193 and CPII21/00003; the ISCIII grants FIS/FEDER 19/1338, 16/1288, 23/1578 and MS20/0006; the European Union grant H2020 874583; the Spanish Ministry of Universities (Margarita Salas Grant MS21-133) and co-funded by European Union - Next Generation EU; the Generalitat Valenciana, grants AICO/2020/285 and CIAICO/2021/132; and the Generalitat de Catalunya, AGAUR grant 2021-SGR-357., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability

  • Román-Álamo, Lucía
  • Avalos-Padilla, Yunuen
  • Bouzón-Arnáiz, Inés
  • Iglesias, Valentin
  • Fernández Lajo, Jorge
  • Monteiro, Juan M.
  • Rivas, Luis
  • Fisa, Roser
  • Riera, Cristina
  • Andreu Martínez, David
  • Pintado-Grima, Carlos
  • Ventura, Salvador
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
The problems associated with the drugs currently used to treat leishmaniasis, including resistance, toxicity, and the high cost of some formulations, call for the urgent identification of new therapeutic agents with novel modes of action. The aggregated protein dye YAT2150 has been found to be a potent antileishmanial compound, with a half-maximal inhibitory concentration (IC50) of approximately 0.5 µM against promastigote and amastigote stages of Leishmania infantum. The encapsulation in liposomes of YAT2150 significantly improved its in vitro IC50 to 0.37 and 0.19 µM in promastigotes and amastigotes, respectively, and increased the half-maximal cytotoxic concentration in human umbilical vein endothelial cells to >50 µM. YAT2150 became strongly fluorescent when binding intracellular protein deposits in Leishmania cells. This fluorescence pattern aligns with the proposed mode of action of this drug in the malaria parasite Plasmodium falciparum, the inhibition of protein aggregation. In Leishmania major, YAT2150 rapidly reduced ATP levels, suggesting an alternative antileishmanial mechanism. To the best of our knowledge, this first-in-class compound is the only one described so far having significant activity against both Plasmodium and Leishmania, thus being a potential drug for the treatment of co-infections of both parasites., This work was supported by grants (i) Fundació La Marató de TV3, Ref. 201811 (X.F.-B.); (ii) PID2021-128325OB-I00 (X.F.-B.) and PID2020-118127RB-I00 (D.M.-T.), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033), which included ERDF funds; (iii) II Premis Innovació Campus Clínic 2022, Hospital Clínic de Barcelona (X.F.-B.); and (iv) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2021-SGR-00635 (S.V.) and 2021-SGR-00357 (D.M.-T.). Work at Pompeu Fabra University was supported by “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409) and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. Work at the Centro de Investigaciones Biológicas was supported by grants from MCIN Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER RD16/0027/0010 and CSIC PIE 201620E038. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen
  • Biosca, Arnau
  • Caño-Prades, Omar
  • Román-Álamo, Lucía
  • Valle, Javier
  • Andreu Martínez, David
  • Moita, Diana
  • Prudêncio, Miguel
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome's propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen's viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC50 of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC50, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite's viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain, A New Indication for Soluble Epoxide Hydrolase Inhibitors

  • Codony, Sandra|||0000-0003-0539-673X
  • Entrena, José M.|||0000-0002-4319-746X
  • Calvó-Tusell, Carla|||0000-0003-2681-8460
  • Jora, Beatrice
  • González-Cano, Rafael|||0000-0002-9657-4521
  • Osuna, Sílvia|||0000-0003-3657-6469
  • Corpas, Rubén|||0000-0002-7051-1493
  • Morisseau, Christophe
  • Pérez, Belén|||0000-0001-5801-1704
  • Barniol-Xicota, Marta|||0000-0001-7957-2199
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel|||0000-0002-6500-792X
  • Martínez, Antón L.|||0000-0002-1595-3459
  • Loza, María Isabel|||0000-0003-4730-0863
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Verhelst, Steven H. L.|||0000-0002-7400-1319
  • Sanfeliu i Pujol, Coral|||0000-0002-9004-1206
  • Feixas, Ferran|||0000-0001-5147-0000
  • Hammock, Bruce D.|||0000-0003-1408-8317
  • Brea, José|||0000-0002-5523-1979
  • Cobos, Enrique J.
  • Vázquez, Santiago|||0000-0002-9296-6026
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field.